An NGS-Based Test for Myeloid Leukemia
What is OncoTarget®Myeloid68
Next-Generation sequencing (NGS) performs massively parallel sequencing of genomes, allowing for the analysis of a significant number of genomic targets with a single test. Critically, NGS allows for the detection of aberrations that may only be present at very low levels, but which may have important clinical relevance for the patient’s diagnosis and prognosis.

GoPath’s MyeloidNGS68 Panel provides actionable information for improved diagnosis, prognosis, and risk stratification for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).
Clinical Values of OncoTarget® Myeloid68
The majority of myeloid tumors harbor high numbers of somatic mutations, which are not inherited but created within the tumor itself. Thus, unlike germline mutations these somatic mutations are not transmitted to offspring. Somatic mutations significantly contribute to the pathogenesis, progression and prognosis of myeloid malignancies.

GoPath’s MyeloidNGS68 Panel consists of 68 genes that targets known mutations associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Testing using this panel can aid in making therapy decisions, predicting prognosis, and can be used in clinical research. This is a generic and comprehensive profiling of myeloid neoplasms.
Myeloid Leukemia Cells
Table 02. Assay performance for detection of the Myeloid panel variants
Assay Sensitivity: 97,4%; Assay Specificity: 100%; Positive Predictive Value (PPV): 100%; Negative Predictive Value (NPV): 100%
True Positive (based on ref data)
MyeloidNGS68 Detected (%)
False Positive
False Negative
Ref Lab Variants
Counts:42 Replicates: 66
65 (98,5%)
GoPath Variants
Counts:12 Replicates: 12
11 (91,7%)
Counts:54 Replicates: 78
76 (97,4%)

Additional testing available

    Three different tests to determine cancer risk – PROSTATENOW™ – Germline test for prostate cancer, BRCANOW® – Hereditary test for breast and ovarian cancer -LYNCHNOW® – Screening to detect lynch syndrome.
  • GoPath® Labs
    Testing for a diagnosis, therapy and monitoring of certain blood disorders including leukemia and lymphoma.
  • OncoTracking™
    Whether a patient is in remission or is currently undergoing treatment, the sooner cancer recurrence or metastasis is found, the sooner the patient can receive appropriate therapy and treatment.
  • OncoTarget®
    Delivering the broadest, FDA-cleared Comprehensive Genomic Profiling for solid tumors.
Ready to place an order for the test?
Additional questions, contact us and our client service team will guide through the process